Trimedyne sues Bard for breach of Urolase marketing agreement.
This article was originally published in The Gray Sheet
TRIMEDYNE SEEKING AT LEAST $72 MIL. FROM BARD IN UROLASE LITIGATION, according to a complaint filed Oct. 6 in the Superior Court of the State of California, Orange County division. Trimedyne claims that Bard willfully neglected a 1991 contract between the two companies relating to the marketing and distribution of the Urolase side-firing laser fiber. The suit specifically charges Bard with breach of contract, fraud, negligent misrepresentation, and failure to pay Trimedyne for expenses agreed upon under terms of the contract.
You may also be interested in...
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.